Ethyl Pyruvate as a Potential Defense Intervention against Cytokine Storm in COVID-19?

Autor:	Tanwar O; Department of Pharmacy, Shri G.S. Institute of Technology and Science, 23, Sir M. Visvesvaraya Marg (Park Road), Indore 452003, Madhya Pradesh, India., Soni A; Department of Pharmacy, Shri G.S. Institute of Technology and Science, 23, Sir M. Visvesvaraya Marg (Park Road), Indore 452003, Madhya Pradesh, India., Prajapat P; Department of Pharmacy, Shri G.S. Institute of Technology and Science, 23, Sir M. Visvesvaraya Marg (Park Road), Indore 452003, Madhya Pradesh, India., Shivhare T; Department of Pharmacy, Shri G.S. Institute of Technology and Science, 23, Sir M. Visvesvaraya Marg (Park Road), Indore 452003, Madhya Pradesh, India., Pandey P; Department of Pharmacy, Shri G.S. Institute of Technology and Science, 23, Sir M. Visvesvaraya Marg (Park Road), Indore 452003, Madhya Pradesh, India., Samaiya PK; Department of Pharmacy, Shri G.S. Institute of Technology and Science, 23, Sir M. Visvesvaraya Marg (Park Road), Indore 452003, Madhya Pradesh, India., Pandey SP; Department of Pharmacy, Shri G.S. Institute of Technology and Science, 23, Sir M. Visvesvaraya Marg (Park Road), Indore 452003, Madhya Pradesh, India., Kar P; Department of Biosciences & Biomedical Engineering, Indian Institute of Technology, Khandwa Road, Simrol, Indore 453552, Madhya Pradesh, India.
Jazyk:	angličtina
Zdroj:	ACS omega [ACS Omega] 2021 Mar 09; Vol. 6 (11), pp. 7754-7760. Date of Electronic Publication: 2021 Mar 09 (Print Publication: 2021).
DOI:	10.1021/acsomega.1c00157
Abstrakt:	COVID-19 is a deadly pandemic and has resulted in a huge loss of money and life in the past few months. It is well known that the SARS-CoV-2 gene mutates relatively slowly as compared to other viruses but still may create hurdles in developing vaccines. Therefore, there is a need to develop alternative routes for its management and treatment of COVID-19. Based on the severity of viral infection in COVID-19 patients, critically ill patients (∼5%, with old age, and comorbidities) are at high risk of morbidities. The reason for this severity in such patients is attributed to "misleading cytokine storm", which produces ARDS and results in the deaths of critically ill patients. In this connection, ethyl pyruvate (EP) controls these cytokines/chemokines, is an anti-inflammatory agent, and possesses a protective effect on the lungs, brain, heart, and mitochondria against various injuries. Considering these facts, we propose that the site-selective EP formulations (especially aerosols) could be the ultimate adjuvant therapy for the regulation of misleading cytokine storm in severely affected COVID-19 patients and could reduce the mortalities. Competing Interests: The authors declare no competing financial interest. (© 2021 The Authors. Published by American Chemical Society.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu